A look at five biotech companies in the cancer market and their upcoming releases at the 2017 American Society of Clinical Oncology (ASCO).
Jounce Therapeutics, a private biotech company headquartered in Cambridge, Massachusetts, inked a licensing and development deal with Celgene Corporation that could hit $2.5 billion.
Sorrento Therapeutics and Servier have inked a license and collaboration deal to develop, manufacture and commercialize products using Sorrento’s STI-A1110.
San Diego-based Arena Pharmaceuticals announced that it is laying off about 100 people as part of a strategic change in priorities.
Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
Astex Pharmaceuticals has forged a deal with Genentech to develop a combination treatment for acute myeloid leukemia (AML).
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of […]
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
January 27, 2016By Mark Terry, BioSpace.com Breaking News Staff Menlo Park, Calif.-based Adicet Bio, Inc. announced today that it had closed on a $51 million Series A financing round. The financing was led by OrbiMed and joined by Novartis Venture Fund and Pontifax. In addition, Adicet announced it had acquired Israeli company Applied Immune […]
BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States. Once BioSpace sorted the companies into that group, they were then weighted by a number of different categories and ranked in a cumulative […]